$10.00
0.30% yesterday
Nasdaq, Jun 11, 10:15 pm CET
ISIN
US46565G1040
Symbol
ITOS
Sector
Industry

ITeos Therapeutics Inc Stock price

$10.00
+3.08 44.51% 1M
+1.70 20.48% 6M
+2.32 30.21% YTD
-6.32 38.73% 1Y
-9.05 47.51% 5Y
-9.05 47.51% 10Y
-9.05 47.51% 20Y
Nasdaq, Closing price Wed, Jun 11 2025
-0.03 0.30%
ISIN
US46565G1040
Symbol
ITOS
Sector
Industry

Key metrics

Market capitalization $382.74m
Enterprise Value $-137.63m
EV/FCF (TTM) EV/FCF 1.37
P/B ratio (TTM) P/B ratio 0.68
Free Cash Flow (TTM) Free Cash Flow $-100.38m
Cash position $520.37m
P/E forward negative
Short interest 9.21%

Is ITeos Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,841 stocks worldwide.

ITeos Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

6 Analysts have issued a ITeos Therapeutics Inc forecast:

1x Buy
17%
5x Hold
83%

Analyst Opinions

6 Analysts have issued a ITeos Therapeutics Inc forecast:

Buy
17%
Hold
83%

Financial data from ITeos Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
35 35
178% 178%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 49 49
2% 2%
140%
- Research and Development Expense 145 145
29% 29%
416%
-158 -158
5% 5%
-452%
- Depreciation and Amortization 1.24 1.24
38% 38%
4%
EBIT (Operating Income) EBIT -160 -160
6% 6%
-456%
Net Profit -134 -134
19% 19%
-384%

In millions USD.

Don't miss a Thing! We will send you all news about ITeos Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

ITeos Therapeutics Inc Stock News

Neutral
GlobeNewsWire
15 days ago
- Board of Directors intends to cease operations - Company to focus efforts on selecting best path to deliver near-term value to shareholders - Exploring potential asset sales including EOS-984, EOS-215, and a preclinical obesity program targeting ENT1 WATERTOWN, Mass. and GOSSELIES, Belgium, May 28, 2025 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceu...
Neutral
GlobeNewsWire
30 days ago
– GALAXIES Lung-201 did not meet established criteria for clinically meaningful improvements in progression free survival
Neutral
GlobeNewsWire
about one month ago
- Topline interim dataset from GALAXIES Lung-201 with >240 patients anticipated in 2Q25 - Interim datasets from GALAXIES H&N-202 and TIG-006 HNSCC with ~200 patients anticipated in 2025 - Cash balance and investment balance of $624.3 million as of March 31, 2025 expected to provide runway through 2027 WATERTOWN, Mass. and GOSSELIES, Belgium, April 28, 2025 (GLOBE NEWSWIRE) -- iTeos Therapeutics...
More ITeos Therapeutics Inc News

Company Profile

iTeos Therapeutics, Inc. engages in the development of biopharmaceuticals therapeutic products and services. It offers immuno-oncology therapeutics for patients. The company was founded by Michel Detheux in April 2012 and is headquartered in Cambridge, MA.

Head office United States
CEO Michel Detheux
Employees 173
Founded 2012
Website www.iteostherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today